

Atty Docket No.: JHV-050.01

Inventor: Tzyy-Chouu Wu *et al.*

Filing Date: May 5, 2004

Application No.: 10/555,669-Conf. #9879

Title: ANTI-CANCER DNA VACCINE EMPLOYING PLASMIDS ENCODING SIGNAL
SEQUENCE, MUTANT ONCO-PROTEIN ANTIGEN, AND HEAT SHOCK PROTEIN

Documents Filed:

- Response to Notification of Missing Requirements (2 pages in dupl.)
- Copy of Notification of Missing Requirements (3 pages)
- Petition for Four Month Extension of Time Under 37 CFR 1.136(a) (1 page in dupl.)
- Paper copy of Sequence Listing (17 pages)
- CRF diskette of Sequence Listing (1 disk)
- Statement to Support Sequence Listing submission (1 page)
- Preliminary Amendment (3 pages)
- Executed Declaration (1 page)
- Executed Powers of Attorney (2 pages)
- Notification of Change of Attorney Docket Number (1 page)

Via: First Class Mail

Sender's Initials: JYA/dmn

RECEIVED

MAR 29 2007

PATENT DEPT
DOCKETING

IAP6 Rec'd PCT/PTO 22 MAR 2007

Atty Docket No.: JHV-050.01

Inventor: Tzyy-Chouu Wu *et al.*

Application No.: 10/555,669-Conf. #9879

Filing Date: May 5, 2004

Title: ANTI-CANCER DNA VACCINE EMPLOYING PLASMIDS ENCODING SIGNAL
SEQUENCE, MUTANT ONCO-PROTEIN ANTIGEN, AND HEAT SHOCK PROTEIN

Documents Filed:

- Response to Notification of Missing Requirements (2 pages in dupl.)
- Copy of Notification of Missing Requirements (3 pages)
- Petition for Four Month Extension of Time Under 37 CFR 1.136(a) (1 page in dupl.)
- Paper copy of Sequence Listing (17 pages)
- CRF diskette of Sequence Listing (1 disk)
- Statement to Support Sequence Listing submission (1 page)
- Preliminary Amendment (3 pages)
- Executed Declaration (1 page)
- Executed Powers of Attorney (2 pages)
- Notification of Change of Attorney Docket Number (1 page)

Via: First Class Mail

Sender's Initials: JYA/dmn

Date: March 19, 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Wu, Tzyy-Chouu *et al.*

Application No: 10/555,669

International Filing Date: May 5, 2004

For: ANTI-CANCER DNA VACCINE
EMPLOYING PLASMIDS ENCODING
SIGNAL SEQUENCE, MUTANT ONCO-
PROTEIN ANTIGEN, AND HEAT
SHOCK PROTEIN

Art Unit: *To be Determined*

Confirmation No.: 9879

Examiner: *To be Determined*

Docket No. JHV-050.01

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that the foregoing documents are being deposited with the United States Postal Service as First Class Mail, in an envelope addressed to Mail Stop PCT (DO/EO/US), Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450, on this date of March 19, 2007.


John Barretto

RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS

Mail Stop PCT (DO/EO/US)
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This paper is being filed in response to the Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US) mailed on September 19, 2006, in the above-referenced application.

Enclosed is a copy of the Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US); a Petition for a Four-Month Extension of Time; a paper copy of the Sequence Listing; a Computer Readable Form of the Sequence Listing (CRF); a Statement to Support the Filing and Submission of the Sequence Listing in accordance with 37 CFR §§1.821-1.825; a Preliminary Amendment; Declaration signed by Inventors Wu and Hung; and Powers of Attorney signed by Inventors Wu and Hung.

Please charge the surcharge for a small entity (\$65.00) to our **Deposit Account No. 06-1148, Reference JHV-050.01**. A copy of this Response is enclosed.

Although we believe that we have submitted the correct amount to cover the above-listed items, the Commissioner is authorized to credit any overpayment or charge any deficiencies to our **Deposit Account No. 06-1448, Reference JHV-050.01.**

Respectfully Submitted,

Date: March 19, 2007


Customer No: 25181

Patent Group

Foley Hoag LLP

155 Seaport Blvd.

Boston, MA 02210-2600



Janann Y. Ali, Ph.D.

Reg. No. 54,958

Agent for Applicants

Tel. (617) 832-1000

Fax. (617) 832-7000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Wu, Tzyy-Chouu *et al.*

Application No: 10/555,669

International Filing Date: May 5, 2004

For: ANTI-CANCER DNA VACCINE
EMPLOYING PLASMIDS ENCODING
SIGNAL SEQUENCE, MUTANT ONCO-
PROTEIN ANTIGEN, AND HEAT
SHOCK PROTEIN

Art Unit: *To be Determined*

Confirmation No.: 9879

Examiner: *To be Determined*

Docket No. JHV-050.01

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that the foregoing documents are being deposited with the United States Postal Service as First Class Mail, in an envelope addressed to Mail Stop PCT (DO/EO/US), Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450, on this date of March 19, 2007.


John Barretto

RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS

Mail Stop PCT (DO/EO/US)
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This paper is being filed in response to the Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US) mailed on September 19, 2006, in the above-referenced application.

Enclosed is a copy of the Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US); a Petition for a Four-Month Extension of Time; a paper copy of the Sequence Listing; a Computer Readable Form of the Sequence Listing (CRF); a Statement to Support the Filing and Submission of the Sequence Listing in accordance with 37 CFR §§1.821-1.825; a Preliminary Amendment; Declaration signed by Inventors Wu and Hung; and Powers of Attorney signed by Inventors Wu and Hung.


Please charge the surcharge for a small entity (\$65.00) to our **Deposit Account No. 06-1448, Reference JHV-050.01**. A copy of this Response is enclosed.

Although we believe that we have submitted the correct amount to cover the above-listed items, the Commissioner is authorized to credit any overpayment or charge any deficiencies to our **Deposit Account No. 06-1448, Reference JHV-050.01.**

Respectfully Submitted,

Date: March 19, 2007

Customer No: 25181
Patent Group
Foley Hoag LLP
155 Seaport Blvd.
Boston, MA 02210-2600



Janann Y. Ali, Ph.D.
Reg. No. 54,958
Agent for Applicants
Tel. (617) 832-1000
Fax. (617) 832-7000



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

52L
JHU-18

U.S. APPLICATION NUMBER NO. 10/555,669	FIRST NAMED APPLICANT Tzyy-Choo Wu	ATTY. DOCKET NO. 26148.1180
---	---------------------------------------	--------------------------------

INTERNATIONAL APPLICATION NO.

PCT/US04/13756

I.A. FILING DATE

05/05/2004

PRIORITY DATE

05/05/2003

McKenna Long & Aldridge
1900 K Street NW
Washington, DC 20006

Missing Requirement

DUE: 11/19/07-w/2 mock +

FINAL: 4/19/07

CONFIRMATION NO. 9879

371 FORMALITIES LETTER



OC000000020495147

Date Mailed: 09/19/2006

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Indication of Small Entity Status
- Copy of the International Application filed on 11/07/2005
- Copy of the International Search Report filed on 11/07/2005
- Preliminary Amendments filed on 11/07/2005
- Information Disclosure Statements filed on 11/07/2005
- U.S. Basic National Fees filed on 11/07/2005
- Priority Documents filed on 11/07/2005

RECEIVED
SEP 21 2006
DOCKETED BY: JVA
DUE DATE: 11/19/06 / FINAL: 4/19/07
ATTORNEY CONFIRMATION:
McKENNA LONG & ALDRIDGE

The applicant needs to satisfy supplemental fees problems indicated below.

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
- To avoid abandonment, a surcharge (for late submission of filing fee, search fee, examination fee or oath or declaration) as set forth in 37 CFR 1.492(h) of \$65 for a small entity in compliance with 37 CFR 1.27, must be submitted with the missing items identified in this letter.

SUMMARY OF FEES DUE:

Total additional fees required for this application is \$65 for a Small Entity:

- \$65 Surcharge.

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application.** Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

JOHN L ANDERSON

Telephone: (703) 308-9140 EXT 211

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/555,669	PCT/US04/13756	26148.1180

FORM PCT/DO/EO/905 (371 Formalities Notice)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop PCT (DO/EU/US), Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: March 19, 2007

Signature:

(John Barretto)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a) FY 2006 (Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).)		Docket Number (Optional) JHV-050.01	
Application Number 10/555,669-Conf. #9879		Filed May 5, 2004	
For ANTI-CANCER DNA VACCINE EMPLOYING PLASMIDS ENCODING SIGNAL SEQUENCE, MUTANT ONCO-PROTEIN ANTIGEN, AND HEAT SHOCK PROTEIN			
Art Unit N/A		Examiner Not Yet Assigned	
This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a reply in the above identified application.			
The requested extension and fee are as follows (check time period desired and enter the appropriate fee below):			
		Fee	Small Entity Fee
<input type="checkbox"/>	One month (37 CFR 1.17(a)(1))	\$120	\$60 \$ _____
<input type="checkbox"/>	Two months (37 CFR 1.17(a)(2))	\$450	\$225 \$ _____
<input type="checkbox"/>	Three months (37 CFR 1.17(a)(3))	\$1020	\$510 \$ _____
<input checked="" type="checkbox"/>	Four months (37 CFR 1.17(a)(4))	\$1590	\$795 \$ 795.00
<input type="checkbox"/>	Five months (37 CFR 1.17(a)(5))	\$2160	\$1080 \$ _____
<input checked="" type="checkbox"/>	Applicant claims small entity status. See 37 CFR 1.27.		
<input type="checkbox"/>	A check in the amount of the fee is enclosed.		
<input type="checkbox"/>	Payment by credit card. Form PTO-2038 is attached.		
<input type="checkbox"/>	The Director has already been authorized to charge fees in this application to a Deposit Account.		
<input checked="" type="checkbox"/>	The Director is hereby authorized to charge any fees which may be required, or credit any overpayment, to 06-1448 Deposit Account Number <u>Ref. JHV-050.01</u> . I have enclosed a duplicate copy of this sheet.		
I am the	<input type="checkbox"/>	applicant/inventor.	
	<input type="checkbox"/>	assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).	
	<input checked="" type="checkbox"/>	attorney or agent of record. Registration Number <u>54,958</u>	
	<input type="checkbox"/>	attorney or agent under 37 CFR 1.34. Registration number if acting under 37 CFR 1.34 _____	
<u>Janann Ali</u> Signature		<u>March 19, 2007</u> Date	
<u>Janann Y. Ali</u> Typed or printed name		<u>(617) 832-1000</u> Telephone Number	
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.			
<input checked="" type="checkbox"/>	Total of <u>2</u> forms are submitted.		

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop PCT (DO/EQ/US), Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: March 19, 2007

Signature: John Barretto (John Barretto)

PC/MS-DOS PATENTIN 3.3
WU, TZZY-CHOOU et al.
Appl. No.: 10/555,669
Filed: 05-MAY-2004
Data Rec: 15-FEB-2007
Atty. Dkt. No: JHV-050.01
(19546-5001)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket No: JHV-050.01 (19546-5001)

In re patent application of

WU, TZZY-CHOUU et al.

Serial No. 10/555,669

Filed: May 5, 2004

For: ANTI-CANCER DNA VACCINE EMPLOYING PLASMIDS ENCODING SIGNAL SEQUENCE,
MUTANT ONCOPROTEIN ANTIGEN, AND HEAT SHOCK PROTEIN

STATEMENT TO SUPPORT FILING AND SUBMISSION IN
ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
Mail Stop SEQUENCE

Sir:

In connection with a Sequence Listing submitted concurrently
herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37
C.F.R. § 1.821(g), does not include new matter;

2. the content of the attached paper copy and the
attached computer readable copy of the Sequence Listing, submitted in
accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same.

Respectfully submitted,

Feb. 15, 2007

Date


James A. Coburn

HARBOR CONSULTING IP SERVICES, INC.
1500A Lafayette Road, #262
Portsmouth, N.H. 03801
800-318-3021

gac ctg tta atg ggc aca cta gga att gtg tgc ccc atc tgt tct cag 288
Asp Leu Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys Ser Gln
85 90 95

gat aag ctt
Asp Lys Leu

297

<210> 2
<211> 99
<212> PRT
<213> Human papillomavirus

<400> 2
Met His Gly Asp Thr Pro Thr Leu His Glu Tyr Met Leu Asp Leu Gln
1 5 10 15
Pro Glu Thr Thr Asp Leu Tyr Cys Tyr Glu Gln Leu Asn Asp Ser Ser
20 25 30
Glu Glu Glu Asp Glu Ile Asp Gly Pro Ala Gly Gln Ala Glu Pro Asp
35 40 45
Arg Ala His Tyr Asn Ile Val Thr Phe Cys Cys Lys Cys Asp Ser Thr
50 55 60
Leu Arg Leu Cys Val Gln Ser Thr His Val Asp Ile Arg Thr Leu Glu
65 70 75 80
Asp Leu Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys Ser Gln
85 90 95
Asp Lys Leu

<210> 3
<211> 98
<212> PRT
<213> Human papillomavirus

<400> 3
Met His Gly Asp Thr Pro Thr Leu His Glu Tyr Met Leu Asp Leu Gln
1 5 10 15
Pro Glu Thr Thr Asp Leu Tyr Cys Tyr Glu Gln Leu Asn Asp Ser Ser
20 25 30
Glu Glu Glu Asp Glu Ile Asp Gly Pro Ala Gly Gln Ala Glu Pro Asp
35 40 45
Arg Ala His Tyr Asn Ile Val Thr Phe Cys Cys Lys Cys Asp Ser Thr
50 55 60
Leu Arg Leu Cys Val Gln Ser Thr His Val Asp Ile Arg Thr Leu Glu
65 70 75 80
Asp Leu Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys Ser Gln
85 90 95
Lys Pro

<210> 4
 <211> 158
 <212> PRT
 <213> Human papillomavirus

<400> 4
 Met His Gln Lys Arg Thr Ala Met Phe Gln Asp Pro Gln Glu Arg Pro
 1 5 10 15
 Arg Lys Leu Pro Gln Leu Cys Thr Glu Leu Gln Thr Thr Ile His Asp
 20 25 30
 Ile Ile Leu Glu Cys Val Tyr Cys Lys Gln Gln Leu Leu Arg Arg Glu
 35 40 45
 Val Tyr Asp Phe Ala Phe Arg Asp Leu Cys Ile Val Tyr Arg Asp Gly
 50 55 60
 Asn Pro Tyr Ala Val Cys Asp Lys Cys Leu Lys Phe Tyr Ser Lys Ile
 65 70 75 80
 Ser Glu Tyr Arg His Tyr Cys Tyr Ser Leu Tyr Gly Thr Thr Leu Glu
 85 90 95
 Gln Gln Tyr Asn Lys Pro Leu Cys Asp Leu Leu Ile Arg Cys Ile Asn
 100 105 110
 Cys Gln Lys Pro Leu Cys Pro Glu Glu Lys Gln Arg His Leu Asp Lys
 115 120 125
 Lys Gln Arg Phe His Asn Ile Arg Gly Arg Trp Thr Gly Arg Cys Met
 130 135 140
 Ser Cys Cys Arg Ser Ser Arg Thr Arg Arg Glu Thr Gln Leu
 145 150 155

<210> 5
 <211> 151
 <212> PRT
 <213> Human papillomavirus

<400> 5
 Met Phe Gln Asp Pro Gln Glu Arg Pro Arg Lys Leu Pro Gln Leu Cys
 1 5 10 15
 Thr Glu Leu Gln Thr Thr Ile His Asp Ile Ile Leu Glu Cys Val Tyr
 20 25 30
 Cys Lys Gln Gln Leu Leu Arg Arg Glu Val Tyr Asp Phe Ala Phe Arg
 35 40 45
 Asp Leu Cys Ile Val Tyr Arg Asp Gly Asn Pro Tyr Ala Val Cys Asp
 50 55 60

Lys Cys Leu Lys Phe Tyr Ser Lys Ile Ser Glu Tyr Arg His Tyr Cys
65 70 75 80

Tyr Ser Leu Tyr Gly Thr Thr Leu Glu Gln Gln Tyr Asn Lys Pro Leu
85 90 95

Cys Asp Leu Leu Ile Arg Cys Ile Asn Cys Gln Lys Pro Leu Cys Pro
100 105 110

Glu Glu Lys Gln Arg His Leu Asp Lys Lys Gln Arg Phe His Asn Ile
115 120 125

Arg Gly Arg Trp Thr Gly Arg Cys Met Ser Cys Cys Arg Ser Ser Arg
130 135 140

Thr Arg Arg Glu Thr Gln Leu
145 150

<210> 6

<211> 378

<212> DNA

<213> Human papillomavirus

<400> 6

atggcgggccc ccggcgcccg gcggccgctg ctctctctgc tgctggcagg ccttgccacat 60
ggcgccctcag cactctttga ggaatctaac atgcattggag atacacctac attgcatgaa 120
tatatgttag attgcaacc agagacaact gatctctact gttatgagca attaaatgac 180
agctcagagg aggaggatga aatagatggt ccagctggac aagcagaacc ggacagagcc 240
cattacaata ttgtaacctt ttgttgcaag tgtgactcta cgcttcgggt gtgcgtacaa 300
agcacacacg tagacattcg tactttggaa gacctgttaa tgggcacact aggaattgtg 360
tgccccatct gtctctcaa 378

<210> 7

<211> 127

<212> PRT

<213> Human papillomavirus

<400> 7

Met Ala Ala Pro Gly Ala Arg Arg Pro Leu Leu Leu Leu Leu Ala
1 5 10 15

Gly Leu Ala His Gly Ala Ser Ala Leu Phe Glu Asp Leu Ile Met His
20 25 30

Gly Asp Thr Pro Thr Leu His Glu Tyr Met Leu Asp Leu Gln Pro Glu
35 40 45

Thr Thr Asp Leu Tyr Cys Tyr Glu Gln Leu Asn Asp Ser Ser Glu Glu
50 55 60

Glu Asp Glu Ile Asp Gly Pro Ala Gly Gln Ala Glu Pro Asp Arg Ala
65 70 75 80

His Tyr Asn Ile Val Thr Phe Cys Cys Lys Cys Asp Ser Thr Leu Arg
85 90 95

Leu Cys Val Gln Ser Thr His Val Asp Ile Arg Thr Leu Glu Asp Leu
100 105 110

Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys Ser Gln Pro
115 120 125

<210> 8

<211> 90

<212> DNA

<213> Human papillomavirus

<400> 8

atggcgccccc ccggcgcccg gggccgctg ctcctgctgc tgcctggcagg ccttgccatc 60
ggcgccctcag cactctttga ggatcctaac 90

<210> 9

<211> 1878

<212> DNA

<213> Mycobacterium tuberculosis

<400> 9

atggctcggt cggtcgggat cgacctcggg accaccaact ccgctcgtctc ggttctggaa 60
gggtgcgacc cggtcgtcgt cgccaactcc gagggtctcca ggaccacccc gtcaattgtc 120
cggttcgccc gcaacgggtga ggtgctggtc ggcagccccc ccaagaacca ggacgtgacc 180
aacgtcgatc gcaacggtgc ctcggtcaag cgacacatgg gcacgcagctg gtccatagag 240
attgacggca agaataacac cgcccgaggag atcagcgccc gcatctgat gaagctgaag 300
cgcgacgcgc aggcctacct cggtgaggac attaccgacg cggttatcac gacgccccgc 360
tacttcaatg acgccccagc tcaggccacc aaggacgcgc gccagatcgc cggcctcaac 420
gtgctcgga tcgtcaacga gccgaccgcg gccgcgctgg cctacggcct cgacaagggc 480
gagaaggagc agcgaatcct ggtcttcgac ttgggtgggtg gcatcttcga cgtttccctg 540
ctggagatcg gcgagggtgt ggttgaggtc cgtgccactt cgggtgacaa ccacctcggc 600
ggcgacgact gggacacagc ggtcgtcgat tggctggttg acaagttcaa gggcaccagc 660
ggcatcgatc tgaccaagga caagatggcg atgcagcggc tgcgggaagc cgccgagaag 720
gcaaagatcg agctgagttc gactcagtc acctcgatca acctgcccta catcacgcgt 780
gacgcgcgaca agaaccggtt gttcttagac gaggagctga ccgcgcggga gttccaacgg 840
atcactcagg acctgctgga ccgcactcgc aagccggttc agtcggtgat cgtcgacacc 900
ggcatttcgt tgcctggagat cgatcacgtt gtgctcgtgg gtggttcgac ccggatgccc 960
cggttgacgc atctggtcaa ggaactcacc ggcggcaagg aacccaacaa gggcgtaaac 1020
cccgatgagg ttgtcgcggt gggagccgct ctgcaggccg ggcgtcctcaa gggcgagggt 1080
aaagacgttc tgcgtcttga tttaccocg ctgagcctgg gtatcgagac caaggcgagg 1140
gtgatgacca ggctcatcga gcgcaacacc acgatcccca ccaagcggtc ggaagacttc 1200
accacgcagc acgacaacca acgctcggtg cagatccagg tctatcagg ggagcgtgag 1260
atcgccgcgc acacaagtt gctcgggtcc ttcgagctga ccggcatccc cgcggcgccg 1320
cgggggattc ccagatcga ggtcacttcc gacatcgacg ccaacggcat tgcgcagctc 1380
accgccaagg acaagggcac cggaaggagg aacacgatcc gaatccaggga aggtcggggc 1440
ctgtccaaag aagacattga ccgcatgatc aaggacgcgc aagcgacgc cgaggaggat 1500
cgcaagcgtc gcgaggaggc cgatggtcgt aatcaagccg agacatttgt ctaccagacg 1560
gagaagtctg tcaagaacaa gcgtgaggcc gagggttggt cgaaggtacc tgaagacagc 1620
tgaaacaagg ttgatgccgc ggtggcgcaa gcgaaggcgc cacttgggcg atccgatatt 1680
tcggccatca agtcggcgat ggagaagctg gccagaggat cgacaggtct ggggcaagcg 1740
atctacgaag cagctcaggc tgcgtcacag ccactggcg ctgccaccc cgcgggcgag 1800
ccggcggtg cccaccccg ctcggtgatc gacgttgttg acgcgagggt ggtcgcagac 1860
ggccgggagg ccaagtga 1878

<210> 10

<211> 625

<212> PRT

<213> Mycobacterium tuberculosis

<400> 10

Met Ala Arg Ala Val Gly Ile Asp Leu Gly Thr Thr Asn Ser Val Val
 1 5 10 15

Ser Val Leu Glu Gly Gly Asp Pro Val Val Val Ala Asn Ser Glu Val
 20 25 30

Ser Arg Thr Thr Pro Ser Ile Val Ala Phe Ala Arg Asn Gly Glu Val
 35 40 45

Leu Val Gly Gln Pro Ala Lys Asn Gln Ala Val Thr Asn Val Asp Arg
 50 55 60

Thr Val Arg Ser Val Lys Arg His Met Gly Ser Asp Trp Ser Ile Glu
 65 70 75 80

Ile Asp Gly Lys Lys Tyr Thr Ala Pro Glu Ile Ser Ala Arg Ile Leu
 85 90 95

Met Lys Leu Lys Arg Asp Ala Glu Ala Tyr Leu Gly Glu Asp Ile Thr
 100 105 110

Asp Ala Val Ile Thr Thr Pro Ala Tyr Phe Asn Asp Ala Gln Arg Gln
 115 120 125

Ala Thr Lys Asp Ala Gly Gln Ile Ala Gly Leu Asn Val Leu Arg Ile
 130 135 140

Val Asn Glu Pro Thr Ala Ala Leu Ala Tyr Gly Leu Asp Lys Gly
 145 150 155 160

Glu Lys Glu Gln Arg Ile Leu Val Phe Asp Leu Gly Gly Gly Thr Phe
 165 170 175

Asp Val Ser Leu Leu Glu Ile Gly Glu Gly Val Val Glu Val Arg Ala
 180 185 190

Thr Ser Gly Asp Asn His Leu Gly Gly Asp Asp Trp Asp Gln Arg Val
 195 200 205

Val Asp Trp Leu Val Asp Lys Phe Lys Gly Thr Ser Gly Ile Asp Leu
 210 215 220

Thr Lys Asp Lys Met Ala Met Gln Arg Leu Arg Glu Ala Ala Glu Lys
 225 230 235 240

Ala Lys Ile Glu Leu Ser Ser Ser Gln Ser Thr Ser Ile Asn Leu Pro
 245 250 255

Tyr Ile Thr Val Asp Ala Asp Lys Asn Pro Leu Phe Leu Asp Glu Gln
 260 265 270

Leu Thr Arg Ala Glu Phe Gln Arg Ile Thr Gln Asp Leu Leu Asp Arg
 275 280 285
 Thr Arg Lys Pro Phe Gln Ser Val Ile Ala Asp Thr Gly Ile Ser Val
 290 295 300
 Ser Glu Ile Asp His Val Val Leu Val Gly Gly Ser Thr Arg Met Pro
 305 310 315 320
 Ala Val Thr Asp Leu Val Lys Glu Leu Thr Gly Gly Lys Glu Pro Asn
 325 330 335
 Lys Gly Val Asn Pro Asp Glu Val Val Ala Val Gly Ala Ala Leu Gln
 340 345 350
 Ala Gly Val Leu Lys Gly Glu Val Lys Asp Val Leu Leu Leu Asp Val
 355 360 365
 Thr Pro Leu Ser Leu Gly Ile Glu Thr Lys Gly Gly Val Met Thr Arg
 370 375 380
 Leu Ile Glu Arg Asn Thr Thr Ile Pro Thr Lys Arg Ser Glu Thr Phe
 385 390 395 400
 Thr Thr Ala Asp Asp Asn Gln Pro Ser Val Gln Ile Gln Val Tyr Gln
 405 410 415
 Gly Glu Arg Glu Ile Ala Ala His Asn Lys Leu Leu Gly Ser Phe Glu
 420 425 430
 Leu Thr Gly Ile Pro Pro Ala Pro Arg Gly Ile Pro Gln Ile Glu Val
 435 440 445
 Thr Phe Asp Ile Asp Ala Asn Gly Ile Val His Val Thr Ala Lys Asp
 450 455 460
 Lys Gly Thr Gly Lys Glu Asn Thr Ile Arg Ile Gln Glu Gly Ser Gly
 465 470 475 480
 Leu Ser Lys Glu Asp Ile Asp Arg Met Ile Lys Asp Ala Glu Ala His
 485 490 495
 Ala Glu Glu Asp Arg Lys Arg Arg Glu Glu Ala Asp Val Arg Asn Gln
 500 505 510
 Ala Glu Thr Leu Val Tyr Gln Thr Glu Lys Phe Val Lys Glu Gln Arg
 515 520 525
 Glu Ala Glu Gly Gly Ser Lys Val Pro Glu Asp Thr Leu Asn Lys Val
 530 535 540
 Asp Ala Ala Val Ala Glu Ala Lys Ala Ala Leu Gly Gly Ser Asp Ile
 545 550 555 560
 Ser Ala Ile Lys Ser Ala Met Glu Lys Leu Gly Gln Glu Ser Gln Ala
 565 570 575

Leu Gly Gln Ala Ile Tyr Glu Ala Ala Gln Ala Ala Ser Gln Ala Thr
580 585 590

Gly Ala Ala His Pro Gly Gly Glu Pro Gly Gly Ala His Pro Gly Ser
595 600 605

Ala Asp Asp Val Val Asp Ala Glu Val Val Asp Asp Gly Arg Glu Ala
610 615 620

Lys
625

<210> 11

<211> 2104

<212> DNA

<213> Artificial Sequence

<220>

<221> CDS

<222> (1)..(2103)

<220>

<223> Description of Artificial Sequence: Synthetic
construct

<400> 11

atg cat gga gat aca cct aca ttg cat gaa tat atg tta gat ttg caa 48
Met His Gly Asp Thr Pro Thr Leu His Glu Tyr Met Leu Asp Leu Gln
1 5 10 15

coa gag aca act gat ctc tac tgt tat gag caa tta aat gac agc tca 96
Pro Glu Thr Thr Asp Leu Tyr Cys Tyr Glu Gln Leu Asn Asp Ser Ser
20 25 30

gag gag gag gat gaa ata gat ggt cca gct gga caa gca gaa ccg gac 144
Glu Glu Glu Asp Glu Ile Asp Gly Pro Ala Gly Gln Ala Glu Pro Asp
35 40 45

aga gcc cat tac aat att gta acc ttt tgt tgc aag tgt gac tct acg 192
Arg Ala His Tyr Asn Ile Val Thr Phe Cys Cys Lys Cys Asp Ser Thr
50 55 60

ctt cgg ttg tgc gta caa agc aca cac gta gac att cgt act ttg gaa 240
Leu Arg Leu Cys Val Gln Ser Thr His Val Asp Ile Arg Thr Leu Glu
65 70 75 80

gac ctg tta atg ggc aca cta gga att gtg tgc ccc atc tgt tct caa 288
Asp Leu Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys Ser Gln
85 90 95

gga tcc atg gct cgt gcg gtc ggg atc gac ctc ggg acc acc aac tcc 336
Gly Ser Met Ala Arg Ala Val Gly Ile Asp Leu Gly Thr Thr Asn Ser
100 105 110

gtc gtc tcg gtt ctg gaa ggt ggc gac ccg gtc gtc gtc gcc aac tcc 384
Val Val Ser Val Leu Glu Gly Gly Asp Pro Val Val Val Ala Asn Ser
115 120 125

gag ggc tcc agg acc acc ccg tca att gtc gcg ttc gcc cgc aac ggt	432
Glu Gly Ser Arg Thr Thr Pro Ser Ile Val Ala Phe Ala Arg Asn Gly	
130 135 140	
gag gtg ctg gtc ggc cag ccc gcc aag aac cag gca gtg acc aac gtc	480
Glu Val Leu Val Gly Gln Pro Ala Lys Asn Gln Ala Val Thr Asn Val	
145 150 155 160	
gat cgc acc gtg cgc tcg gtc aag cga cac atg ggc agc gac tgg tcc	528
Asp Arg Thr Val Arg Ser Val Lys Arg His Met Gly Ser Asp Trp Ser	
165 170 175	
ata gag att gac ggc aag aaa tac acc gcg ccg gag atc agc gcc cgc	576
Ile Glu Ile Asp Gly Lys Lys Tyr Thr Ala Pro Glu Ile Ser Ala Arg	
180 185 190	
att ctg atg aag ctg aag cgc gac gcc gag gcc tac ctc ggt gag gac	624
Ile Leu Met Lys Leu Lys Arg Asp Ala Glu Ala Tyr Leu Gly Glu Asp	
195 200 205	
att acc gac gcg gtt atc acg acg ccc gcc tac ttc aat gac gcc cag	672
Ile Thr Asp Ala Val Ile Thr Thr Pro Ala Tyr Phe Asn Asp Ala Gln	
210 215 220	
cgt cag gcc acc aag gac gcc gcc cag atc gcc gcc ctc aac gtg ctg	720
Arg Gln Ala Thr Lys Asp Ala Gly Gln Ile Ala Gly Leu Asn Val Leu	
225 230 235 240	
cgg atc gtc aac gag ccg acc gcg gcc gcg ctg gcc tac ggc ctc gac	768
Arg Ile Val Asn Glu Pro Thr Ala Ala Leu Ala Tyr Gly Leu Asp	
245 250 255	
aag ggc gag aag gag cag cga atc ctg gtc ttc gac ttg ggt ggt ggc	816
Lys Gly Glu Lys Glu Gln Arg Ile Leu Val Phe Asp Leu Gly Gly Gly	
260 265 270	
act ttc gac gtt tcc ctg ctg gag atc ggc gag ggt gtg gtt gag gtc	864
Thr Phe Asp Val Ser Leu Leu Glu Ile Gly Glu Gly Val Val Glu Val	
275 280 285	
cgt gcc act tcg ggt gac aac cac ctc gcc gcc gac gac tgg gac cag	912
Arg Ala Thr Ser Gly Asp Asn His Leu Gly Gly Asp Asp Trp Asp Gln	
290 295 300	
cgg gtc gtc gat tgg ctg gtg gac aag ttc aag gcc acc agc gcc atc	960
Arg Val Val Asp Trp Leu Val Asp Lys Phe Lys Gly Thr Ser Gly Ile	
305 310 315 320	
gat ctg acc aag gac aag atg gcg atg cag cgg ctg cgg gaa gcc gcc	1008
Asp Leu Thr Lys Asp Lys Met Ala Met Gln Arg Leu Arg Glu Ala Ala	
325 330 335	
gag aag gca aag atc gag ctg agt tcg agt cag tcc acc tcg atc aac	1056
Glu Lys Ala Lys Ile Glu Leu Ser Ser Ser Gln Ser Thr Ser Ile Asn	
340 345 350	

ctg ccc tac atc acc gtc gac gcc gac aag aac ccg ttg ttc tta gac	1104
Leu Pro Tyr Ile Thr Val Asp Ala Asp Lys Asn Pro Leu Phe Leu Asp	
355 360 365	
gag cag ctg acc cgc gcg gag ttc caa cgg atc act cag gac ctg ctg	1152
Glu Gln Leu Thr Arg Ala Glu Phe Gln Arg Ile Thr Gln Asp Leu Leu	
370 375 380	
gac cgc act cgc aag ccg ttc cag tgc gtg atc gct gac acc ggc att	1200
Asp Arg Thr Arg Lys Pro Phe Gln Ser Val Ile Ala Asp Thr Gly Ile	
385 390 395 400	
tcg gtg tgc gag atc gat cac gtt gtg ctc gtg ggt ggt tgc acc cgg	1248
Ser Val Ser Glu Ile Asp His Val Val Leu Val Gly Gly Ser Thr Arg	
405 410 415	
atg ccc gcg gtg acc gat ctg gtc aag gaa ctc acc ggc ggc aag gaa	1296
Met Pro Ala Val Thr Asp Leu Val Lys Glu Leu Thr Gly Gly Lys Glu	
420 425 430	
ccc aac aag ggc gtc aac ccc gat gag gtt gtc gcg gtg gga gcc gct	1344
Pro Asn Lys Gly Val Asn Pro Asp Glu Val Val Ala Val Gly Ala Ala	
435 440 445	
ctg cag gcc ggc gtc ctc aag ggc gag gtg aaa gac gtt ctg ctg ctt	1392
Leu Gln Ala Gly Val Leu Lys Gly Glu Val Lys Asp Val Leu Leu Leu	
450 455 460	
gat gtt acc ccg ctg agc ctg ggt atc gag acc aag ggc ggg gtg atg	1440
Asp Val Thr Pro Leu Ser Leu Gly Ile Glu Thr Lys Gly Gly Val Met	
465 470 475 480	
acc agg ctc atc gag cgc aac acc acg atc ccc acc aag cgg tgc gag	1488
Thr Arg Leu Ile Glu Arg Asn Thr Thr Ile Pro Thr Lys Arg Ser Glu	
485 490 495	
act ttc acc acc gcc gac gac aac caa ccg tgc gtg cag atc cag gtc	1536
Thr Phe Thr Thr Ala Asp Asp Asn Gln Pro Ser Val Gln Ile Gln Val	
500 505 510	
tat cag ggg gag cgt gag atc gcc gcg cac aac aag ttg ctc ggg tcc	1584
Tyr Gln Gly Glu Arg Glu Ile Ala Ala His Asn Lys Leu Gly Ser	
515 520 525	
ttc gag ctg acc ggc atc ccg ccg gcg ccg cgg ggg att ccg cag atc	1632
Phe Glu Leu Thr Gly Ile Pro Pro Ala Pro Arg Gly Ile Pro Gln Ile	
530 535 540	
gag gtc act ttc gac atc gac gcc aac ggc att gtg cac gtc acc gcc	1680
Glu Val Thr Phe Asp Ile Asp Ala Asn Gly Ile Val His Val Thr Ala	
545 550 555 560	
aag gac aag ggc acc ggc aag gag aac acg atc cga atc cag gaa ggc	1728
Lys Asp Lys Gly Thr Gly Lys Glu Asn Thr Ile Arg Ile Gln Glu Gly	
565 570 575	

tcg ggc ctg tcc aag gaa gac att gac cgc atg atc aag gac gcc gaa 1776
 Ser Gly Leu Ser Lys Glu Asp Ile Asp Arg Met Ile Lys Asp Ala Glu
 580 585 590

gcg cac gcc gag gag gat cgc aag cgt cgc gag gag gcc gat gtt cgt 1824
 Ala His Ala Glu Glu Asp Arg Lys Arg Glu Glu Ala Asp Val Arg
 595 600 605

aat caa gcc gag aca ttg gtc tac cag acg gag aag ttc gtc aaa gaa 1872
 Asn Gln Ala Glu Thr Leu Val Tyr Gln Thr Glu Lys Phe Val Lys Glu
 610 615 620

cag cgt gag gcc gag ggt ggt tcg aag gta cct gaa gac acg ctg aac 1920
 Gln Arg Glu Ala Glu Gly Gly Ser Lys Val Pro Glu Asp Thr Leu Asn
 625 630 635 640

aag gtt gat gcc gcg gtg gcg gaa gcg aag gcg gca ctt ggc gga tcg 1968
 Lys Val Asp Ala Ala Val Ala Glu Ala Lys Ala Ala Leu Gly Gly Ser
 645 650 655

gat att tcg gcc atc aag tcg gcg atg gag aag ctg gcc cag gag tcg 2016
 Asp Ile Ser Ala Ile Lys Ser Ala Met Glu Lys Leu Gly Gln Glu Ser
 660 665 670

cag gct ctg ggg caa gcg atc tac gaa gca gct cag gct gcg tca cag 2064
 Gln Ala Leu Gly Gln Ala Ile Tyr Glu Ala Ala Gln Ala Ala Ser Gln
 675 680 685

gcc act ggc gct gcc cac ccc ggc tcg gct gat gaa agc a 2104
 Ala Thr Gly Ala Ala His Pro Gly Ser Ala Asp Glu Ser
 690 695 700

<210> 12

<211> 701

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
 construct

<400> 12

Met His Gly Asp Thr Pro Thr Leu His Glu Tyr Met Leu Asp Leu Gln
 1 5 10 15

Pro Glu Thr Thr Asp Leu Tyr Cys Tyr Glu Gln Leu Asn Asp Ser Ser
 20 25 30

Glu Glu Glu Asp Glu Ile Asp Gly Pro Ala Gly Gln Ala Glu Pro Asp
 35 40 45

Arg Ala His Tyr Asn Ile Val Thr Phe Cys Cys Lys Cys Asp Ser Thr
 50 55 60

Leu Arg Leu Cys Val Gln Ser Thr His Val Asp Ile Arg Thr Leu Glu
 65 70 75 80

Asp Leu Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys Ser Gln
 85 90 95

Gly Ser Met Ala Arg Ala Val Gly Ile Asp Leu Gly Thr Thr Asn Ser
 100 105 110

Val Val Ser Val Leu Glu Gly Gly Asp Pro Val Val Val Ala Asn Ser
 115 120 125

Glu Gly Ser Arg Thr Thr Pro Ser Ile Val Ala Phe Ala Arg Asn Gly
 130 135 140

Glu Val Leu Val Gly Gln Pro Ala Lys Asn Gln Ala Val Thr Asn Val
 145 150 155 160

Asp Arg Thr Val Arg Ser Val Lys Arg His Met Gly Ser Asp Trp Ser
 165 170 175

Ile Glu Ile Asp Gly Lys Lys Tyr Thr Ala Pro Glu Ile Ser Ala Arg
 180 185 190

Ile Leu Met Lys Leu Lys Arg Asp Ala Glu Ala Tyr Leu Gly Glu Asp
 195 200 205

Ile Thr Asp Ala Val Ile Thr Thr Pro Ala Tyr Phe Asn Asp Ala Gln
 210 215 220

Arg Gln Ala Thr Lys Asp Ala Gly Gln Ile Ala Gly Leu Asn Val Leu
 225 230 235 240

Arg Ile Val Asn Glu Pro Thr Ala Ala Ala Leu Ala Tyr Gly Leu Asp
 245 250 255

Lys Gly Glu Lys Glu Gln Arg Ile Leu Val Phe Asp Leu Gly Gly Gly
 260 265 270

Thr Phe Asp Val Ser Leu Leu Glu Ile Gly Glu Gly Val Val Glu Val
 275 280 285

Arg Ala Thr Ser Gly Asp Asn His Leu Gly Gly Asp Asp Trp Asp Gln
 290 295 300

Arg Val Val Asp Trp Leu Val Asp Lys Phe Lys Gly Thr Ser Gly Ile
 305 310 315 320

Asp Leu Thr Lys Asp Lys Met Ala Met Gln Arg Leu Arg Glu Ala Ala
 325 330 335

Glu Lys Ala Lys Ile Glu Leu Ser Ser Ser Gln Ser Thr Ser Ile Asn
 340 345 350

Leu Pro Tyr Ile Thr Val Asp Ala Asp Lys Asn Pro Leu Phe Leu Asp
 355 360 365

Glu Gln Leu Thr Arg Ala Glu Phe Gln Arg Ile Thr Gln Asp Leu Leu
 370 375 380

Asp Arg Thr Arg Lys Pro Phe Gln Ser Val Ile Ala Asp Thr Gly Ile
 385 390 395 400
 Ser Val Ser Glu Ile Asp His Val Val Leu Val Gly Gly Ser Thr Arg
 405 410 415
 Met Pro Ala Val Thr Asp Leu Val Lys Glu Leu Thr Gly Gly Lys Glu
 420 425 430
 Pro Asn Lys Gly Val Asn Pro Asp Glu Val Val Ala Val Gly Ala Ala
 435 440 445
 Leu Gln Ala Gly Val Leu Lys Gly Glu Val Lys Asp Val Leu Leu Leu
 450 455 460
 Asp Val Thr Pro Leu Ser Leu Gly Ile Glu Thr Lys Gly Gly Val Met
 465 470 475 480
 Thr Arg Leu Ile Glu Arg Asn Thr Thr Ile Pro Thr Lys Arg Ser Glu
 485 490 495
 Thr Phe Thr Thr Ala Asp Asp Asn Gln Pro Ser Val Gln Ile Gln Val
 500 505 510
 Tyr Gln Gly Glu Arg Glu Ile Ala Ala His Asn Lys Leu Leu Gly Ser
 515 520 525
 Phe Glu Leu Thr Gly Ile Pro Pro Ala Pro Arg Gly Ile Pro Gln Ile
 530 535 540
 Glu Val Thr Phe Asp Ile Asp Ala Asn Gly Ile Val His Val Thr Ala
 545 550 555 560
 Lys Asp Lys Gly Thr Gly Lys Glu Asn Thr Ile Arg Ile Gln Glu Gly
 565 570 575
 Ser Gly Leu Ser Lys Glu Asp Ile Asp Arg Met Ile Lys Asp Ala Glu
 580 585 590
 Ala His Ala Glu Glu Asp Arg Lys Arg Arg Glu Glu Ala Asp Val Arg
 595 600 605
 Asn Gln Ala Glu Thr Leu Val Tyr Gln Thr Glu Lys Phe Val Lys Glu
 610 615 620
 Gln Arg Glu Ala Glu Gly Gly Ser Lys Val Pro Glu Asp Thr Leu Asn
 625 630 635 640
 Lys Val Asp Ala Ala Val Ala Glu Ala Lys Ala Ala Leu Gly Gly Ser
 645 650 655
 Asp Ile Ser Ala Ile Lys Ser Ala Met Glu Lys Leu Gly Gln Glu Ser
 660 665 670
 Gln Ala Leu Gly Gln Ala Ile Tyr Glu Ala Ala Gln Ala Ala Ser Gln
 675 680 685

Ala Thr Gly Ala Ala His Pro Gly Ser Ala Asp Glu Ser
690 695 700

<210> 13
<211> 6681
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
vector

<400> 13
gctccgcccc cctgacgagc atcacaaaaa tcgacgctca agtcagaggt ggcgaaaccc 60
gacagagacta taagaatacc aggcgtttcc cctcggaagc gctctcctgt 120
tcgaccctgt ccgcttacgc gatacctctc cgcctttctc ccttcgggaa gcgtggcgct 180
ttctcatagc tcacgctgta ggtatctcag ttcggtgtag gtcgctcgct ccaagctggg 240
ctgtgtgcac gaaccccccg ttacgcccga ccgctgcgcc ttatccggta actatcgctc 300
tgagtccaac ccggtaaagc acgacttatc gccactggca gcagccactg gtaacaggat 360
tagcagagcg aggtatgtag gcggtgtctac agagttcttg aagtggtggc ctaactacgg 420
ctacactaga agaacagtat ttggtatctg cgcctctgctg aagccagtta ccttcggaaa 480
aagagttgggt agctcttgat ccggcaaaaa aaccacgcgt ggtagcgggt gttttttgt 540
ttgcaagcag cagattacgc gcagaaaaaa aggatctcaa gaagatcctt tgatcttttc 600
tacgggggtg gacgtcagtg ggaacgaaaa ctcaogttaa gggattttgg tcatgagatt 660
atcaaaaaag atcttcaact agatcctttt aaattaaaaa tgaagtttta aatcaactta 720
aagtatatat gagttaactt ggtctgacag ttaccaatgc ttaactcagt aggcacactat 780
ctcagcgatc tgtctatttc gttcatccat agttgcctga ctccggggggg gggggcgctg 840
aggtctgcct cgtgaagaag gtgtgtctga ctcataccag ggcaacggtg ttgccattcg 900
tacaggcgtc gctgtgtcac gctcgtcgtt tggtatggct tcattcagct ccggtttcca 960
acgatcaagg cgagttacat gatcccccat gttgtgcaaa aaagcgggta gctccttcgg 1020
tcctcogate gttgtcagaa gtaagttggc cgcagtgcta tcactcatgg ttagggcagc 1080
actgcataat tctcttactg tcatgccatc cgtaagatgc ttttctgtga ctgggtgagta 1140
ctcaaccaag tcttctgtag aatagtgtat gcggcgacgc agttgctctt gcccgcgctc 1200
aatccgggat aataccgcgc cacatagcag aactttaaaa gtgctcatca ctggaaaaacg 1260
ttctctgggg cgaaaaactc caaggatctt accgctgttg agatccagtt cgaatgaacc 1320
cactcgtgca cctgaatcgc cccatcatcc agccagaaaag tgagggagcc acggttgatg 1380
agagctttgt tgtagggtga ccagttgggt aatttgaact ttgtccttgc ccggaacgg 1440
tctcgttgtt ccggaagatg cgtgatctga tctctcaact tccttcaagt tcgatttatt 1500
caacaaagcg gccgtccctg caagtacgcy taatgtctgt ccagtggtac aaccaataaa 1560
ccaatctgca ttagaaaaaac tcatcgagca tcaaatgaaa tcgaatatta ttcatatcag 1620
gattatcaat accataatct tgaaaaaagc gtttctgtaa tgaaggagaa aactcaccca 1680
ggcagttcca taggatggca agatcctggt atcggtctgc gattccgact gctcccaact 1740
caatacaacc tattaatttc cctcgtcaa aaataaggtt atcaagttag aaatcaccat 1800
gagtgacgca tgaatccggt gagaatggca aaagcttatg catttctttc cagactgtgtt 1860
caacagggca gccattacgc togtcatcaa aatcactcgc atcaaccaaa ccgttattca 1920
ttcgtgattg cgcctgagcg agacgaaata ccgcgacgct gttaaaaagga caattacaaa 1980
caggaaatgc atgaaacggc gcgaggaaaca ctgcccagca atcaacaata ttttaccctg 2040
aatcaggata ttcttctaat acctggaatg ctgttttccc ggggaatcgca gtgggtgagta 2100
acctgcacac atcagagta cggataaaat gcttgatggg cgggaatagc ataaattccg 2160
tcagccagtt tagcttgacc atctcatctg taacatcatt ggcaacgcta cctttggcat 2220
gttttcagaaa caactctggc gcacggcgct tccatacaaa tcgatagatt gtcgacctg 2280
attgcccagc attatcgcca gccattttat acccaataaa atcagcatcc atgttgggat 2340
ttaatccgcg cctcagcgaa gacgtttccc gttgaatatg gctcataaca cctcttgat 2400
tactgtttat gtaagcagac agtttttatt ttoatgatga tatattttta tcttgtgcga 2460
tgttaacatca gagattttga gacacaaagt ggctttcccc ccccccccat tattgaagca 2520
tttatcaggg ttattgtctc atgagcgcat acatatttga atgtatttag aaaaataaac 2580

aaataggggt	tccgcgcaca	tttccccgaa	aaagtccacc	tgaagcttaa	gaaaccatta	2640
ttatcatgac	atfaacctat	aaaaataggc	gtatcacgag	gccctttcgt	ctcgccggt	2700
tcggtgatga	cggtgaaaac	ctctgacaca	tgacgtcccc	ggagacgggtc	acagcttgct	2760
tgtaagccga	tgcggggagc	agacaagccc	gtcagggggc	gtcagcggtg	gttggcggtg	2820
gtcggggctg	gcttaacctat	gcggtcatcg	agcagattgt	actgagagtg	caccatagtc	2880
ggtgtgaagt	accgcacaga	tgcgtaagga	gaaaataccg	catcagattg	gctattggcc	2940
attgcatacg	ttgtatccat	atcataatat	gtacatttat	atgtgctcat	gtcccaactt	3000
accgccaagt	tgacattgat	tattgactag	tattataatg	taatacaata	cggggtcatt	3060
agttcatagc	ccatatatgg	agttccgctg	tacataaact	accgtaaatg	gcccgccctg	3120
ctgacccgcc	aacgcacccc	gcccatgtac	gtcaataatg	actgatgttc	ccatagtaac	3180
gccaatggcc	actttccatt	gacgtcaatg	gtgggagtat	tacgggttaa	ctgcccaact	3240
ggcagtagat	caagtgtatc	atatgccaa	tacgccccct	atcgagctca	atgacggtaa	3300
atggcccgcc	tggcattatg	cccagtagat	gaccttatgg	gaactttcta	cttggcagta	3360
catctacgta	ttagtcatcg	ctattaccat	ggtgatgcgg	ttttggcagt	acatacaatg	3420
gcgtggatag	cgggtttgact	cacggggatt	tccaagtctc	caccccatgt	acgtcaatgt	3480
gagtttgttt	tggcaccaaa	atcaacggga	ctttccaaaa	tgctgtaaca	actccgcccc	3540
attgacgcaa	atgggcggta	ggcgtgtacg	gtgggaggtc	tatataagca	gagctcgttt	3600
agtgaaacgt	cagatcgccct	ggagacgcca	tccaactgtg	tttgacotcc	atagaagaca	3660
ccgggacgca	tccagcctcc	ggcgccggga	acgggtgcat	ggaaacggga	ttccccctgc	3720
caagagtgc	gtaagtacgc	cctatagact	ctataggcac	accccttggc	ctcttatgca	3780
tgctatactg	tttttggctt	ggggccctata	cacccccgct	tcccttatgct	ataggtgatg	3840
gtatagctta	gacctatagg	gtgggttatt	gacctattat	gaccaactca	acgggtgagg	3900
gcagttgagt	ctgagcagta	ctcgttgctg	ccgcgcgcgc	caccagacat	ataagctgac	3960
agactaacag	actgttccct	tccatgggtc	ttttctgag	taccctcgct	cgacgggtac	4020
gataagctgt	atatcgaatt	ctccgacgga	tcttatggcg	gcccccgggc	ccggcgccgc	4080
gctgctcctg	ctcgtctggg	caggcccttg	acatggcgcc	tcagcactct	ttgaggattc	4140
aatcatgcat	ggagatacac	ctacattgca	tgaatatatg	ttagatttgc	aaccagagac	4200
aactgatctc	tacggttatg	ggcaattaaa	tgacagctca	gaggaggagc	atgaaataga	4260
tggtcgacgt	ggacaagcag	aaccggacag	agccccattac	aaatattgaa	ccctttgtgt	4320
caagtgtgac	tctacgtctc	ggttgtgcgt	acaaagcaca	cacgtagaca	ttcgactatt	4380
ggaagactgc	ttaatgggca	cactaggaat	tgtgtgcccc	atctgtcttc	aaggatccat	4440
ggctcgtgcy	gtcgggatcg	acctcgggac	caccaactcc	gtcgtctcgg	ttctgggaag	4500
tggcgacgct	gtcgtcgctg	ccaaactcga	gggctccagg	accacccctg	caattgtcgc	4560
gttcgccccg	aacggtgagg	tgtcgttcgg	ccagcccggc	aagaacccagg	ccgtagacca	4620
cgtcgatcgc	accgtgcgct	cggtaaacgc	acacatgggc	agcgactggt	cctatagagat	4680
tgacggcaga	aaatacaacc	cgccggagat	cagcgccgcg	attctgatga	agctgaagcg	4740
cgacgcgcga	gcctacactg	gtgaggacat	taccgacgcg	gttatcacga	gcgcccgctc	4800
cttcaatgac	ggccacgctc	aggccaccaa	ggacgcggcg	cagatcgccg	gacctcaact	4860
gtcgggattg	gtcaacgagc	cgaccgcggc	cgcgctggcc	tccggctcgc	acaaggggca	4920
gaaggagcag	cgaatcctgg	tcttcgactt	gggtgggtgc	actttcgacg	tttccctgct	4980
ggagatcgcc	gaggggtgtg	ttgaggtccg	tgccacttcg	gggtgacaacc	acctcgggcg	5040
cgcagactgg	gacacgcggg	tcgtcgattg	gctgtgggac	aagttcaagg	gcaccaacgg	5100
catcgatcgc	accaagggca	agatggcgat	gcagcggtcg	cgggaaagccg	ccggaagaagg	5160
aaagatcgag	ctgagttcga	gtcagtcac	ctcgactaca	tcacccgtca	tcacccgtca	5220
cgccgaccaa	aaccgcttgt	tcttagacga	cgacgtgacc	cgccgggagt	tccaacggat	5280
cactcaggac	ctcgtggacc	gcaactcgaa	gcogttccag	tcggtgatcg	ctgacacggc	5340
catcttcggt	toggagatcg	atcacgttgt	gctcgtgggt	ggttcgaccc	ggatgcccg	5400
gttgacagat	ctcgtcaagg	aaactcacgg	cggcaaggaa	cccaacaagg	gcgtcaaccc	5460
cgatgaggtt	gtcgggtggg	gagccgctct	gcaggccggc	gtccctcaagg	gcgaggtgaa	5520
agacgttctg	ctcgttgatg	ttaccocgct	gagcctgggt	atcgagacca	agggcggggt	5580
gtgacacagg	ctcatcgagc	gcaacacccac	gatccccacc	aagcggctcg	agactttcac	5640
caccgcgcac	gacaaccaac	cgtcgggtgca	gatccaggtc	tatcaggggg	agcgtgagat	5700
cgccgcgcac	acaaggattg	tcgggtcctt	cgagctgacc	ggcatccgcg	cgccgcgcgc	5760
ggggatccgc	cagatcgagg	tcactttcga	catcgacgcg	aacggcattg	tgacgtcac	5820
cgccaaggac	aaggggcacg	gcaggagaaa	acagatccga	atccaggagg	gctcgggctc	5880
gtccaaggaa	gacattgacc	gcattgatcaa	ggacgcggaa	gcgcacgcgc	aggaaggtac	5940
caagcgtcgc	gaggaggcgc	atggttcgtaa	tcaaggccag	acatttgctt	accagacgga	6000
gaagtctcgt	aaagaacagc	gtgaggccga	gggtggttcg	aaggtaccctg	aagaacacgt	6060

```

gaacaaggtt gatgccgagg tggcggaagc gaaggcggca cttggcggat cggatatttc 6120
ggccatacaag tggcgatagg agaagctggg ccaggagtcg caggctctgg ggcaagcgat 6180
ctacgaagca gctcaggctg cgtcacaggc cactggcgct gccaccaccg gctcggctga 6240
tgaaagctta agtttaaacc gctagcctag agcggccgag gatccagatc ttttccctc 6300
tgccaaaaat tatggggaca tcatgaagcc ccttgagcat ctgactctcg gctaataaag 6360
gaaatttatt ttcatgcaa tagtggttg gaattttttg tgtctctcac tcggaaggac 6420
atatgggagg gcaaatcatt taaaacatca gaatgagtat ttggtttaga gtttggcaac 6480
atatgcccat tcttccgctt cctcgtcac tgactcgtg cgctcggtcg ttccgctgcg 6540
gcgagcggtt tcagctcact caaaggcggt aatacgggta tccacagaat caggggataa 6600
gcagggaaag aacatgtgag caaaaggcca gcaaaaggcc aggaaccgta aaaaggccgc 6660
gttgctggcg tttttccata g                                     6681

```

<210> 14

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic primer

<400> 14

ctgatctcta cggttatggg caattaaatg acagctc

37

<210> 15

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic primer

<400> 15

gagctgtcat ttaattgccc ataaccgtag agatca

36

<210> 16

<211> 9

<212> PRT

<213> Human papillomavirus

<400> 16

Arg Ala His Tyr Asn Ile Val Thr Phe

1

5

<210> 17

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<221> CDS

<222> (1)..(21)

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 17

ctc tac tgt tat gag caa tta
Leu Tyr Cys Tyr Glu Gln Leu

21

1

5

<210> 18

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 18

Leu Tyr Cys Tyr Glu Gln Leu

1

5

<210> 19

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<221> CDS

<222> (1)..(21)

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 19

ctc tac ggt tat ggg caa tta
Leu Tyr Gly Tyr Gly Gln Leu

21

1

5

<210> 20

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 20

Leu Tyr Gly Tyr Gly Gln Leu

1

5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Wu, Tzyy-Chouu *et al.*

Application No: 10/555,669

International Filing Date: May 5, 2004

For: ANTI-CANCER DNA VACCINE
EMPLOYING PLASMIDS ENCODING
SIGNAL SEQUENCE, MUTANT ONCO-
PROTEIN ANTIGEN, AND HEAT
SHOCK PROTEIN

Art Unit: *To be Determined*

Confirmation No.: 9879

Examiner: *To be Determined*

Docket No. JHV-050.01

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that the foregoing documents are being deposited with the United States Postal Service as First Class Mail, in an envelope addressed to Mail Stop PCT (DO/EO/US), Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450, on this date of March 19, 2007.


John Barretto

PRELIMINARY AMENDMENT

Mail Stop PCT (DO/EO/US)
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir/Madam:

Prior to substantive examination of the above-referenced patent application, please amend the application as follows:

Amendments to the specification begin on page 2 of this paper.

Remarks begin on page 3 of this paper.

AMENDMENTS TO THE SPECIFICATION

Please replace the paragraph beginning on page 8, line 13 with the following amended paragraph:

Figure 5A is a schematic diagram of the pNGVL4a-Sig/E7 (detox) /HSP70 plasmid vector used for anti-tumor vaccination. ~~Indicated are various inserts and p~~ Fig. 5B discloses SEQ ID NOs: 17-20, respectively, in order of appearance.

Please replace the paragraph beginning on page 34, line 6 with the following amended paragraph:

A portion of SEQ ID NO: 13 ~~above vector showing by annotation~~ annotated with the Sig, E7 (detox) and HSP-70 regions is shown below (nucleotides 3951-6350 of SEQ ID NO: 13). The vector sequence is in lower case; the signal peptide (Sig) is bold italic and annotated over the lines. The E7 (detox) sequence is upper case underscored (and annotated over the lines). The HSP70 sequence is italicized and underscored[[.]] (not bolded) and is also annotated over the lines.

REMARKS


The foregoing amendments have been made to correct typographical errors and to insert the required SEQ ID NO identifiers associated with various listed sequences. No new matter has been added.

CONCLUSION

Applicants respectfully request entry of the present Preliminary Amendment. Early and favorable consideration of the application is respectfully solicited. The Examiner may address any questions raised by this submission to the undersigned at (617) 832-1000. The Commissioner is hereby authorized to charge any necessary fees to our **Deposit Order Account No. 06-1448, reference JHV-050.01.**

Respectfully submitted,
FOLEY HOAG

Dated: March 19, 2007
Customer Number 25181
Patent Group
Foley Hoag LLP
155 Seaport Blvd.
Boston, MA 02210-2600
Tel: (617) 832-1000
FAX: (617) 832-7000


Janann Y. Ali, Ph.D.
Reg. No. 54,958
Agent for Applicant

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)	
Title of Invention	ANTI-CANCER DNA VACCINE EMPLOYING PLASMIDS ENCODING SIGNAL SEQUENCE, MUTANT ONCOPROTEIN ANTIGEN, AND HEAT SHOCK PROTEIN
As the below named inventor(s), I/we declare that:	
This declaration is directed to:	
<input type="checkbox"/> The attached application, or <input checked="" type="checkbox"/> Application No. <u>PCT/US04/13756</u> , filed on <u>05/05/2004</u> , <input checked="" type="checkbox"/> as amended on <u>11/07/2005</u> (if applicable);	
I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;	
I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;	
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.	
WARNING: Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.	
All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.	
FULL NAME OF INVENTOR(S)	
Inventor one:	<u>Tzyy-Choo Wu</u>
Signature:	<u>[Signature]</u> Citizen of: <u>USA</u>
Inventor two:	<u>Chien-Fu Hung</u>
Signature:	<u>[Signature]</u> Citizen of: <u>Taiwan</u>
Inventor three:	
Signature:	
Inventor four:	
Signature:	
<input type="checkbox"/> Additional inventors or a legal representative are being named on _____ additional form(s) attached hereto.	

POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM	Application Number 10/555,669-Conf. #9879	
	Filing Date May 5, 2004	
	First Named Inventor Tzyy-Choo Wu	
	Title	ANTI-CANCER DNA VACCINE EMPLOYING PLASMIDS ENCODING SIGNAL SEQUENCE, MUTANT ONCO-PROTEIN ANTIGEN, AND HEAT SHOCK PROTEIN
	Art Unit	N/A
	Examiner Name	Not Yet Assigned
Attorney Docket No. JHV-050.01		

I hereby revoke all previous powers of attorney given in the above-identified application.

I hereby appoint:

☒ Practitioners associated with the Customer Number: 25181

OR

☐ Practitioner(s) named below:

Name	Registration Number	Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

☒ The address associated with the above-mentioned Customer Number:

OR

☐ The address associated with Customer Number:

OR

☐ Firm or Individual Name:

Address:

City	State	Zip	
Country	Telephone	Email	

I am the:

☒ Applicant/Inventor.

☐ Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record

Signature	Date
Name	Telephone
Title and Company	

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

☒ *Total of 2 forms are submitted.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM	Application Number 10/555,669-Conf. #9879	
	Filing Date May 5, 2004	
	First Named Inventor Tzyy-Choo Wu	
	Title ANTI-CANCER DNA VACCINE EMPLOYING PLASMIDS ENCODING SIGNAL SEQUENCE, MUTANT ONCO-PROTEIN ANTIGEN, AND HEAT SHOCK PROTEIN	
	Art Unit N/A	
Examiner Name Not Yet Assigned		
Attorney Docket No. JHV-050.01		

I hereby revoke all previous powers of attorney given in the above-identified application.

I hereby appoint:

☒ Practitioners associated with the Customer Number: 25181

OR

☐ Practitioner(s) named below:

Name	Registration Number	Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

☒ The address associated with the above-mentioned Customer Number:

OR

☐ The address associated with Customer Number:

☐ Firm or Individual Name:

Address

City	State	Zip	
Country	Telephone	Email	

I am the:

☒ Applicant/Inventor.

☐ Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record

Signature <i>Chien-Fu Hung</i>	Date 2/21/07
Name Chien-Fu Hung	Telephone 410-502-8215
Title and Company Inventor	

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

☒ *Total of 2 forms are submitted.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Wu, Tzyy-Chouu *et al.*

Application No: 10/555,669

International Filing Date: May 5, 2004

For: ANTI-CANCER DNA VACCINE
EMPLOYING PLASMIDS ENCODING
SIGNAL SEQUENCE, MUTANT ONCO-
PROTEIN ANTIGEN, AND HEAT
SHOCK PROTEIN

Art Unit: *To be Determined*

Confirmation No.: 9879

Examiner: *To be Determined*

Docket No. JHV-050.01

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that the foregoing documents are being deposited with the United States Postal Service as First Class Mail, in an envelope addressed to Mail Stop PCT (DO/EO/US), Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450, on this date of March 19, 2007.


John Barretto

NOTIFICATION OF CHANGE OF ATTORNEY DOCKET NUMBER

Mail Stop PCT (DO/EO/US)
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The Attorney Docket Number of the above-identified patent application has changed. Please take notice that the *correct* Attorney Docket Number for this application should now be as follows:


JHV-050.01

Please reference **JHV-050.01** on all future correspondence to the attorney of record.

Respectfully Submitted,

Date: March 19, 2007

Customer No: 25181
Patent Group
Foley Hoag LLP
155 Seaport Blvd.
Boston, MA 02210-2600


Janann F. Ali, Ph.D.
Reg. No. 54,958
Agent for Applicants
Tel. (617) 832-1000
Fax. (617) 832-7000